Company profile for CureGene Pharmaceutical

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

CureGene is a leading biotechnology company focused on innovative gene therapies for cancer and genetic disorders. With a strong commitment to advancing precision medicine, CureGene leverages cutting-edge technologies, including gene editing and viral vector systems, to develop transformative treatments. The company's pipeline includes therapies targeting both solid tumors and hematological malignancies. CureGene strives to br...
CureGene is a leading biotechnology company focused on innovative gene therapies for cancer and genetic disorders. With a strong commitment to advancing precision medicine, CureGene leverages cutting-edge technologies, including gene editing and viral vector systems, to develop transformative treatments. The company's pipeline includes therapies targeting both solid tumors and hematological malignancies. CureGene strives to bring life-changing treatments to patients worldwide, underpinned by its expertise in gene therapy, research, and development.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
No. 1976 Gaoke Middle Road, Shanghai Pilot Free Trade Zone, Shanghai, China
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/curegene-unveils-groundbreaking-preclinical-data-for-cg-0416-a-novel-oral-non-glp-1-therapy-at-obesity-week-2025-302612212.html

PR NEWSWIRE
11 Nov 2025

https://www.prnewswire.com/news-releases/2025-easl-congress-spotlight-cg-0416-preclinical-data-unveils-a-groundbreaking-dual-action-therapy-targeting-obesity-and-mash-302458236.html

PR NEWSWIRE
16 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty